Skba Capital Management LLC reduced its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 13.5% during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund owned 211,800 shares of the company’s stock after selling 33,000 shares during the period. Eli Lilly and makes up 2.6% of Skba Capital Management LLC’s investment portfolio, making the stock its 10th largest holding. Skba Capital Management LLC’s holdings in Eli Lilly and were worth $17,431,000 as of its most recent SEC filing.
A number of other institutional investors have also modified their holdings of LLY. BlackRock Inc. boosted its holdings in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock valued at $5,236,731,000 after acquiring an additional 59,978,664 shares in the last quarter. Vanguard Group Inc. boosted its holdings in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock valued at $5,769,694,000 after acquiring an additional 2,181,701 shares in the last quarter. Winslow Capital Management LLC boosted its holdings in shares of Eli Lilly and by 79.7% in the first quarter. Winslow Capital Management LLC now owns 3,875,968 shares of the company’s stock valued at $326,008,000 after acquiring an additional 1,719,538 shares in the last quarter. Harbour Capital Advisors LLC boosted its holdings in shares of Eli Lilly and by 7,919.1% in the second quarter. Harbour Capital Advisors LLC now owns 1,705,338 shares of the company’s stock valued at $20,721,000 after acquiring an additional 1,684,072 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its holdings in shares of Eli Lilly and by 93.6% in the first quarter. Renaissance Technologies LLC now owns 2,980,400 shares of the company’s stock valued at $250,681,000 after acquiring an additional 1,441,200 shares in the last quarter. 75.66% of the stock is currently owned by institutional investors.
In other news, major shareholder Lilly Endowment Inc sold 190,000 shares of the firm’s stock in a transaction dated Friday, September 15th. The shares were sold at an average price of $82.53, for a total transaction of $15,680,700.00. Following the completion of the transaction, the insider now owns 123,682,287 shares in the company, valued at approximately $10,207,499,146.11. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In the last 90 days, insiders have sold 770,000 shares of company stock valued at $64,669,850. Insiders own 0.20% of the company’s stock.
Several analysts have recently weighed in on the stock. BMO Capital Markets set a $73.00 target price on shares of Eli Lilly and and gave the company a “sell” rating in a report on Tuesday, October 24th. Barclays PLC lifted their target price on shares of Eli Lilly and from $90.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 13th. Berenberg Bank reiterated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research note on Thursday, October 26th. Zacks Investment Research cut shares of Eli Lilly and from a “buy” rating to a “hold” rating in a research note on Monday. Finally, Jefferies Group LLC reiterated a “buy” rating and issued a $96.00 price objective (up previously from $93.00) on shares of Eli Lilly and in a research note on Thursday, July 13th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have given a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $89.76.
TRADEMARK VIOLATION WARNING: This news story was posted by Community Financial News and is the sole property of of Community Financial News. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.com-unik.info/2017/11/03/skba-capital-management-llc-lowers-holdings-in-eli-lilly-and-company-lly.html.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings data on Tuesday, October 24th. The company reported $1.05 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.03 by $0.02. Eli Lilly and had a net margin of 9.90% and a return on equity of 30.27%. The company had revenue of $5.66 billion during the quarter, compared to analyst estimates of $5.52 billion. During the same quarter last year, the firm posted $0.88 EPS. The business’s revenue for the quarter was up 9.0% on a year-over-year basis.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 8th. Stockholders of record on Wednesday, November 15th will be given a dividend of $0.52 per share. The ex-dividend date of this dividend is Tuesday, November 14th. This represents a $2.08 annualized dividend and a dividend yield of 2.50%. Eli Lilly and’s dividend payout ratio (DPR) is 98.58%.
Eli Lilly and Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
What are top analysts saying about Eli Lilly and Company? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Eli Lilly and Company and related companies.